Exchange & Returns Information
Review Details
(0)
| Generic For | ADRUCIL |
|---|---|
| Active Ingredient | FLUOROURACIL |
| Strength | 1%W/W |
| Manufacturer | MENARINI |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 3 BOXES - 3 TUBES | $ 2.53 | $ 7.60 |
$ 6.46
Apply ZARVY26 (-15%)
You save $ 1.14
|
||
| 6 BOXES - 6 TUBES | $ 3.37 | $ 20.20 |
$ 17.17
Apply ZARVY26 (-15%)
You save $ 3.03
|
||
| ★ Best Value 10 BOXES - 10 TUBES | $ 3.90 | $ 39.00 |
$ 33.15
Apply ZARVY26 (-15%)
You save $ 5.85
|
Reference information will be available soon.
Flonida 1% Cream is a topical formulation containing 1% w/w fluorouracil, a pyrimidine antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. This action selectively targets dysplastic or neoplastic skin cells while sparing healthy tissue. It is primarily used in dermatologic oncology for treating actinic keratosis, superficial basal cell carcinoma, and Bowen’s disease. As a non-invasive alternative to surgery, it is valued for its ability to induce localized cell death through topical application, triggering a cycle of inflammation, necrosis, and skin renewal.
AntiCancer Drugs > Actinic Keratosis
Indicated for treating precancerous lesions caused by chronic sun exposure. Fluorouracil cream induces a controlled inflammatory reaction that leads to shedding of atypical keratinocytes and eventual skin regeneration.
Superficial Basal Cell Carcinoma
Used as a non-surgical topical treatment for small, low-risk basal cell carcinomas when excision is not feasible. Acts by targeting cancerous cells in the epidermis.
Bowen’s Disease
Applied for carcinoma in situ of the skin. Offers a nonsurgical, skin-preserving treatment option by selectively destroying intraepidermal malignant cells.
Off-label Dermatologic Use
May be used in specific cases under physician guidance for conditions such as warts, keloids, and HPV-related cutaneous lesions, although not officially approved for these indications.
Inhibits thymidylate synthase, blocking DNA replication in abnormal skin cells
Selectively targets dysplastic and cancerous cells with minimal systemic absorption
Induces inflammation followed by necrosis and reepithelialization
Provides a non-invasive, cosmetically favorable option in dermatologic oncology
Actinic Keratosis
1% Cream: Apply twice daily in a thin layer covering all lesions
Duration: 2 to 4 weeks depending on tolerance and lesion severity
Healing Phase: Inflammation peaks and subsides within 1–2 weeks after discontinuation
Superficial Basal Cell Carcinoma
5% Cream: Apply twice daily
Duration: 3 to 6 weeks, extendable to 12 weeks in some cases
Only 5% strength is recommended for this indication
Application Notes:
Wash hands before and after use
Wait 10 minutes after cleansing the skin before applying
Avoid eyes, lips, nostrils, and mucous membranes
Expect erythema → blistering → crusting → healing sequence
Discontinue and consult physician if severe ulceration occurs
Storage Conditions
Store below 25°C in a tightly closed container. Avoid direct sunlight, heat, and moisture.
Restrictions
Do not freeze.
Safety & Disposal
Keep out of reach of children. Discard any unused cream after expiration or prolonged exposure.
Common
redness, burning, itching, dryness, scaling at application site
Expected
local inflammation, crusting, peeling, erosion as treatment response
Severe (rare)
secondary infection, ulceration, delayed healing
Precautions
avoid prolonged exposure to sunlight or tanning lamps during treatment
Monitoring
inspect treated area regularly and report unresponsive or worsening lesions
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
